Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05836324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 408
- Enrollment target
- 20
- Study locations
NCT05836324 is a Phase 1 study of Advanced Solid Tumors and Solid Tumors that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 408 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (108% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05836324, a Phase 1 study of Advanced Solid Tumors and Solid Tumors, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 408 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG FOLFIRI
- DRUG FOLFOX
- DRUG bevacizumab
- DRUG INCA33890
Study Locations (20)
Other
- Rigshospitalet Uni of Hospital of Copenhagen - Copenhagen
- Herlev Og Gentofte Hospital - Herlev
- Odense University Hospital - Odense C
- Vejle Hospital - Vejle
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Fondazione Irccs Istituto Nazionale Dei Tumori - Milan
- Irccs Istituto Clinico Humanitas - Rozzano
- Centro Ricerche Cliniche Di Verona - Verona
California
- The Angeles Clinic and Research Institute - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
New York
- Nyu Langone Health - Long Island Hospital - Mineola
- Laura and Isaac Perlmutter Cancer Center - New York
Texas
- University of Texas Md Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Cancer and Hematology Centers of Western Michigan-Start Midwest - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2027-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05836324
The ClinicalTrials.gov registry entry for NCT05836324 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (108% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Cetuximab is the first listed.
NCT05836324 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05836324 about?
NCT05836324 is a clinical study titled "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors". To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
What is the current status of trial NCT05836324?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 408 participants. The study started on 2023-07-24. Estimated completion is 2027-01-13.
What conditions does trial NCT05836324 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Solid Tumors, Metastatic Solid Tumors.
What interventions are being tested in trial NCT05836324?
The interventions under investigation include: Cetuximab (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), bevacizumab (DRUG), INCA33890 (DRUG).
Who is sponsoring clinical trial NCT05836324?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05836324 being conducted?
This trial has 20 study locations across California, Massachusetts, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.